今年已有30家医药企业拟赴港上市

Core Viewpoint - The recent trend of pharmaceutical companies applying for listings on the Hong Kong Stock Exchange (HKEX) is driven by a focus on innovation, with approximately 30 companies having submitted applications since the beginning of the year, including Jingxin Pharmaceutical, which aims to transition towards innovative drugs [1][3][5]. Group 1: Company Developments - Jingxin Pharmaceutical submitted its application for H-share listing on February 11, 2023, marking its entry into the A+H dual listing journey [3][4]. - The company specializes in two core disease areas: central nervous system diseases and cardiovascular diseases, and has shifted its focus from intermediates and raw materials to innovative drug development [3][4]. - For 2024, Jingxin Pharmaceutical projects total revenue of 4.159 billion yuan and a net profit of 719 million yuan, with R&D investment estimated at 384 million yuan [3]. Group 2: Industry Trends - The trend of pharmaceutical companies seeking listings in Hong Kong is characterized by a significant number of biotech firms, with 13 of the 30 applicants being unprofitable biotech companies [5][6]. - The HKEX's 18A chapter allows unprofitable biotech companies to list, providing them with opportunities for financing and enhancing their market presence [6][7]. - The A+H listing trend is notable, with companies like Baipusais, Dize Pharmaceutical, and Yifang Bio also applying for listings this year, indicating a broader movement among A-share companies to access international capital [8][9]. Group 3: Financial Insights - Baipusais expects a net profit of 160 to 190 million yuan for the previous year, reflecting a year-on-year growth of 29.21% to 53.43% [8]. - Dize Pharmaceutical anticipates a reduced loss of approximately 8.98% year-on-year, while Yifang Bio projects a net loss of 292 million yuan, indicating ongoing high R&D investments despite financial challenges [8][9]. Group 4: Market Implications - The influx of pharmaceutical companies into the HKEX is expected to enhance their capital structure and reduce financing costs, as the market tends to offer higher valuations for innovative drug companies [9]. - The competitive landscape may lead to a rapid differentiation in valuations, as companies will need to demonstrate commercial viability and clinical milestones post-listing [7].